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Abstract
Background: Pain patients are often depressed and anxious, and benefit less from psychotropic drugs than pain-free patients. We
hypothesize that this partial resistance is due to the unique neurochemical contribution to mood by afferent pain projections through the
spino-parabrachial-hypothalamic-amygdalar systems and their projections to other mood-mediating systems. New psychotropic drugs for
pain patients might target molecules in such brain systems. We propose a method to prioritize molecular targets by studying polymorphic
genes in cohorts of patients undergoing surgical procedures associated with a variable pain relief response. We seek molecules that show
a significant statistical interaction between (1) the amount of surgical pain relief, and (2) the alleles of the gene, on depression and anxiety
during the first postoperative year.
Results: We collected DNA from 280 patients with sciatica due to a lumbar disc herniation, 162 treated surgically and 118 non-surgically,
who had been followed for 10 years in the Maine Lumbar Spine Study, a large, prospective, observational study. In patients whose pain
was reduced >25% by surgery, symptoms of depression and anxiety, assessed with the SF-36 Mental Health Scale, improved briskly at the
first postoperative measurement. In patients with little or no surgical pain reduction, mood scores stayed about the same on average.
There was large inter-individual variability at each level of residual pain. Polymorphisms in three pre-specified pain-mood candidate genes,
catechol-O-methyl transferase (COMT), serotonin transporter, and brain-derived neurotrophic factor (BDNF) were not associated with
late postoperative mood or with a pain-gene interaction on mood. Although the sample size did not provide enough power to persuasively
search through a larger number of genes, an exploratory survey of 25 other genes provides illustrations of pain-gene interactions on
postoperative mood – the mu opioid receptor for short-term effects of acute sciatica on mood, and the galanin-2 receptor for effects of
unrelieved post-discectomy pain on mood one year after surgery.
Conclusion: Genomic analysis of longitudinal studies of pain, depression, and anxiety in patients undergoing pain-relieving surgery may
help to identify molecules through which pain alters mood. Detection of alleles with modest-sized effects will require larger cohorts.
Published: 19 April 2006
Molecular Pain 2006, 2:14 doi:10.1186/1744-8069-2-14
Received: 06 March 2006
Accepted: 19 April 2006
This article is available from: http://www.molecularpain.com/content/2/1/14
© 2006 Max et al; licensee BioMed Central Ltd. 
This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), 
which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
Page 2 of 15
(page number not for citation purposes)
Background
Decades of cross-sectional surveys have shown that
chronic pain, depression, and anxiety often coexist. How-
ever, data derived from a single time point is consistent
with diverse causal links [1] e.g., that (1) pain causes
mood or anxiety disorders; (2) these affective disorders
increase pain; (3) a common biological predisposition
underlies both pain and affective disorders; or (4) pain or
affective disorder do not directly cause the other but fre-
quently associate with a "true" causal variable such as
somatization, occupational or social stress, or ineffective
coping style.
Recent reports have more directly examined the direction
of causation by assessing pain and mood over time in
thousands of individuals. In primary care practices and
diverse occupational settings, mood or anxiety disorder at
baseline predicts the subsequent onset of any chronic
pain syndrome [2]; chronic widespread pain [3]; or
chronic low back [4], neck [5], abdominal [6] or shoulder,
arm, or knee pain [7]. Chronic pain at baseline predicts
later anxiety or depressive symptoms [2]. Treatment of
depression in patients with osteoarthritis reduces pain
one year later [8].
Although these studies have strengthened the evidence for
bidirectional causal links between pain and mood, the
designs are not suited for inferring physiological mecha-
nisms. A crucial limitation is that idiopathic "central pain
amplification" or "multisomatoform" conditions [9] were
mixed with conditions in which a measurable structural
injury dominates the pain phenotype. To optimize mech-
anistically-oriented clinical studies one should collect rel-
atively homogeneous patient samples and assess putative
physiological mediators. Predominantly structurally
determined pains may have a different causal relationship
to mood than multisomatoform pains. Cohorts with pain
caused by common and measurable structural lesions like
acute surgical wounds or degenerative joint disease would
be expected to resemble the general population in preva-
lence of previous affective disorder. In patients with mul-
tisomatoform pains, however, lifetime prevalence of
depressive and anxiety disorders is triple that of the gen-
eral population [10]. In these patients, some feature of
brain physiology may predispose to both pain and mood
disorders, and it may be more challenging to tease out
causal relations between pain and affect.
We propose a method to investigate the following
hypothesis: Depression and anxiety triggered or worsened by
pain are mediated by anatomical and neurochemical links that
differ in part from those mediating depression and anxiety dis-
orders that occur independent of pain. A corollary is that opti-
mal treatment of the pain patient's mood disorder might
require different types of antidepressant or anxiolytic
drugs than those effective in pain-free patients. This
hypothesis is based on the neuroanatomical finding that
spinal cord and brainstem pain-signaling neurons project
via the parabrachial and solitary nuclei to densely inner-
vate the hypothalamus, amygdala, nucleus accumbens,
medial orbital cortex, cingulum, and other brain struc-
tures mediating mood [11], and the clinical observation
that the presence of pain renders depressed patients rela-
tively resistant to antidepressant drugs [12]. We predict
that genetic analysis of inter-individual variability of pain-
related mood change (Fig. 1) will identify novel therapeu-
tic targets in these neural connections, whose molecular
components are just beginning to be defined [13].
An economical approach to searching for these molecular
mediators is to piggyback on existing longitudinal studies
of painful diseases caused by definite structural lesions
that include serial pain measurements and standard qual-
ity of life questionnaires. Most such questionnaires assess
depression and anxiety. Perturbations of affect on these
measures, although not diagnostic of clinical disorder,
provide a convenient assessment of these negative emo-
tions. To pursue this approach, we collected DNA from
former participants in a large study of surgical and non-
operative treatment of sciatica caused by intervertebral
disc herniation [14,15]. Discectomy variably relieves
patient's pain with effects occurring soon after a uniform
time point, creating a quasi-experimental design for test-
ing the effects of pain on later mood. In this sciatica study
and others ([16] and RR Edwards et al., in preparation),
baseline mood accounts for only a small component of
the pain relief afforded by discectomy, so one can get a
clearer look at the effect of pain on later mood.
In this paper we present a descriptive analysis of mood
during the year following surgery, and illustrate a method
for detecting genetic polymorphisms that predispose to
pain-influenced mood and or anxiety disorders. This
approach adapts a gene-environment interaction model
that has been proposed to facilitate the detection of genes
that predispose to psychiatric disorders in the presence of
specific quantified stressors, such as the interaction of
serotonin transporter polymorphisms and life stress to
influence depression [17], and of monoamine oxidase
polymorphism and parental abuse to influence conduct
disorder [18]. In the current paper, we are defining the
lumbar spine, nerve root, and its pain input to the central
nervous system as part of the "environment" in which the
brain generates an affective state.
Methods
Patients
Participants were members of the sciatica group of the
Maine Lumbar Spine Study (MLSS [14]), a prospective
cohort study conducted by approximately half of Maine'sMolecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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orthopedists and neurosurgeons who actively treat spine
disease [19]. Patients were enrolled between 1990 and
1992, and surgical or nonsurgical treatment was deter-
mined by clinician judgment and patient preference.
Patients completed questionnaires at study entry, after 3,
6, and 12 months, and then annually through year 10.
Individuals who initially embarked on nonsurgical treat-
ment but elected surgery at or before month 6 were
included in the surgical group because recent data was
available to serve as a baseline. Patients who crossed over
to surgery after month 6 were not included in this study
because the "baseline" may have occurred 6–12 months
preoperatively. After completion of the 10-year study, the
NIDCR and MLSS investigators developed a collaboration
to collect DNA from consenting patients, under a protocol
approved by the NIDCR Institutional Review Board. Of
the 277 patients treated surgically, 162 contributed DNA.
We also collected DNA from 118 patients treated nonsur-
gically and included them in our analysis of pain and
mood scores at baseline. We did not include nonsurgical
patients in genetic analyses of late mood change because
this group was smaller, often lacked confirmatory spine
imaging studies, and was probably more heterogeneous
with regard to underlying pathology and treatment. More-
over, their changes in pain during the early months of the
study were much smaller and more gradual than the sur-
gical group [15]. This temporal course does not offer as
clear an experimental model as the abrupt one-time surgi-
cal perturbation of pain.
Pain measure
The primary measure of pain for this pain-mood study
was the Bodily Pain intensity item on the Short-Form-36
(SF-36) quality of life instrument [20] at baseline, 3, and
6 months. Patients responded to the question "How
much bodily pain have you had during the past 4 weeks?"
by choosing from "very severe," "severe," "moderate,"
"mild," "very mild," and "none." This has been a standard
scale used in analgesic clinical trials for more than 50
years. As part of the SF-36, the scale has been shown to be
reliable and to be sensitive to changes in pain produced by
joint replacement [20].
Hypothesis regarding variability in depression and anxiety observed one year after lumbar discectomy Figure 1
Hypothesis regarding variability in depression and anxiety observed one year after lumbar discectomy. Two 
types of genetic contribution to one-year mood scores are shown. (1) Mood genes currently studied by biological psychia-
trists may contribute to the late mood effects of a stressful surgical illness. Because the diagnosis and treatment are shared by 
all participants, and one can measure residual pain and surgical delay as "environmental variables" and correct for their effect 
on moo, this design may enhance the sensitivity to detect gene effects, compared to designs that study affective disorders in 
patients with widely varying life stressors. These influences would show up in the statistical analysis as main effects on late 
mood. (2) Pain-mood genes may alter the direct effects of pain upon mood, possibly by effects on signaling molecules in the 
dense connections between spinal pain afferent inputs and mood-processing brain structures such as hypothalamus, amygdala, 
nucleus accumbens, medial orbital cortex, and cingulum. These gene effects would vary with the amount of residual chronic 
pain after surgery; i.e., they would show up as significant interactions between gene and pain levels in their effects upon mood.
Baseline depression/anxiety
Delayed surgery
Workers’ compensation
Baseline pain
Herniated Disc
Back + Leg Pain
median ~ 3 mos
Discectomy
Pain-Mood Genes
Pain at 3-6 
months
Depression,
Anxiety at 1 yr
Mood GenesMolecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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Depression and anxiety measures
The mood measure was the Mental Health (MH) subscale
of the SF-36 health survey. This subscale includes three
Likert scale items about the frequency in the previous
month of depressed vs. happy moods, and two items
about the frequency of anxious vs. peaceful moods, each
with 6 possible responses ranging from "all of the time" to
"none of the time." Because depressive and anxious symp-
toms usually coexist in medically ill patients, the develop-
ers of the scale combined the items into a single score,
which correlates closely with DSM-IV psychiatric diag-
noses [21].
Choice of mood candidate genes
In order to control the false-positive error rate in this
modestly sized sample, prior to data analyses we chose
three high-priority candidate polymorphisms that we pre-
dicted would be associated with pain-related mood dete-
rioration:
(1) The met allele at the val158met polymorphism in the
catechol-O-methyltransferase gene (COMT) reduces the
ability of the enzyme to metabolize catecholamines, and
has been associated with variability in an experimentally
evoked pain threshold and unpleasant pain-related affect
[22] and with anxiety disorders [23].
(2) The short allele in the intron 2 tandem repeat poly-
morphism of the serotonin transporter gene (SLC6A4)
lowers the level of expression of the transporter protein
[24] and alters cerebral processing of fear stimuli [25].
This allele has been associated with neuroticism and the
risk of lifetime major depression [26]; and with depres-
sion related to stressful life events [18].
(3) The met allele of the val66met polymorphism in the
brain-derived neurotrophic factor gene (BDNF) lowers
activity-induced secretion of this trophic factor. The met
allele has been associated with geriatric depression [27]
and anxious temperament [28].
In addition to the a priori selection of three putative mood
genes, we carried out exploratory analyses of polymor-
phisms in 25 additional genes that we had previously gen-
otyped for pain genetics studies. We recognized that
correction for multiple testing a cohort of several hundred
patients [29] might render these analyses suitable only for
generating hypotheses for future study. The genes were:
galanin; galanin receptors 1, 2, and 3; interleukin (IL)-1α
and β; IL-1 receptor antagonist; IL-6; IL-10; IL-13; tumor
necrosis factor α; adrenergic receptors 2A, 2B, and 2C; mu
opioid receptor; glial cell derived neurotrophic factor
(GDNF); tyrosine hydroxylase; kainate-3 glutamate recep-
tor; downstream regulatory element antagonistic modula-
tor (DREAM); bradykinin receptors B1 and B2;
chemokine receptor 5; purinergic receptor ligand-gated
ion channel P2X4; calcium channel, voltage-dependent,
α2/δ subunit 2; and chemokine (C-X-C motif) ligand 5
(ENA-CXCL5).
Genotyping methods
SNP markers
The physical position and frequency of minor alleles
(>0.05) from a commercial database (Celera Discovery
System, CDS) were used to select SNPs spaced at 2–5 kb
intervals throughout each gene region plus 4–6 kb
upstream and 4–6 kb downstream of each gene. Allele fre-
quencies of markers and their locations in the genes
described in the Results appear in Additional file 1.
Genomic DNA
Genomic DNA was extracted from lymphoblastoid cell
lines and diluted to a concentration of 5 ng/µl. Two-µl
aliquots were dried in 384-well plates.
Polymerase Chain Reaction (PCR) amplification
Genotyping was performed by the 5' nuclease method
[30] using fluorogenic allele-specific probes. Oligonucle-
otide primer and probe sets were designed based on gene
sequences from the CDS. Reactions were performed in a 5
µl volume containing 2.25 µl TE (ABI Assays On
Demand) or 2.375 µl TE (ABI Assays By Design), 2.5 µl
PCR Master Mix (ABI, Foster City, CA), 10 ng genomic
DNA, 900 nM of each forward and reverse primer, and
100 nM of each reporter and quencher probe. DNA was
incubated at 50°C for 2 min and at 95°C for 10 min, and
amplified on an ABI 9700 device for 40 cycles at 92°C
(ABI Assays on Demand) or 95°C (ABI Assays By Design)
for 15 s and 60°C for1 min. Allele-specific signals were
distinguished by measuring endpoint 6-FAM or VIC fluo-
rescence intensities at 508 nm and 560 nm, respectively,
and genotypes were generated using Sequence Detection
System V.1.7 (ABI). Genotyping error rate was directly
determined by re-genotyping 25% of the samples, ran-
domly chosen, for each locus. The overall error rate was
<0.005. Genotype completion rate was 0.96.
Inference of haplotypes
Haplotype phases – i.e., how the directly measured SNP
alleles were distributed into two chromosomes in each
patient – were inferred by the expectation-maximization
(EM) algorithm (SAS/Genetics, Cary, North Carolina,
USA).
Statistical analysis
We specified as our primary analysis the test of the inter-
action between a (1) particular genetic polymorphism
and (2) the mean bodily pain at the 3 and 6 month post-
operative time points in predicting the SF-36 MH at 12
months. The secondary analysis was the same analysis car-Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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ried out on the baseline SF-36 MH score, examining the
effect of genotype, baseline pain score, and their interac-
tion. This latter analysis included patients who elected
non-surgical treatment as well. If there is no interaction,
the functions describing bodily pain as a contributor to
mood (i.e., regression of mood on bodily pain) are the
same across the different SNP genotypes. The initial selec-
tion of covariates from the MLSS dataset was based upon
the chronic pain literature and winnowed by modeling of
the data prior to analyzing for genotypes. We pre-specified
the additive model as most plausible for the effects of 0,
1, or 2 copies of a polymorphism on mood but also car-
ried out analyses of dominant and recessive models.
Results
Relation between pain and mood
Baseline pain and mood
Fig 2 shows the relation at study baseline between the SF-
36 bodily pain intensity question and the SF-36 MH sub-
scale (top panel) and its items assessing depression (mid-
dle) and anxiety (bottom) in 276 patients, including those
who subsequently underwent surgical or non-surgical
treatment. Consistent with the literature, patients' scores
on anxiety and depression items were closely correlated (r
= 0.68, p < 0.001). Table 1 shows the results of a regres-
sion analysis of contributions to the variance in baseline
symptoms of depression and anxiety. High baseline pain
(about 13% of variance), receiving workers' compensa-
tion (5% of variance), prolonged pain prior to presenta-
tion (3% of variance), and younger age (1% of variance)
were significantly associated with more symptoms of
depression and anxiety over the month before presenta-
tion.
Time course of mood after successful or unsuccessful discectomy
153 surgical patients provided baseline and 3 month
questionnaires and DNA. We divided these patients into
four groups according to the percent reduction they
reported on the 0–5 point SF-36 bodily pain intensity
from pre-surgical baseline to the first postoperative obser-
vation at 3 months: 75–100%, 50–75%, 25–50%, and ≤
25%. Fig 3a (top left) shows the time course of bodily pain
intensity over 3 years for the four quartiles. Fig 3b (top
right) shows the time course of SF-36 MH; and Figs 3c and
3d (bottom) break this down into the items of the SF-36
MH relating to depression and anxiety, considered sepa-
rately.
The baseline points in Figs 3b–d show little difference in
mood between the groups at baseline, suggesting that fac-
tors other than baseline mood account for most of the
large inter-individual differences in surgical relief of pain.
At the three-month time point, the three groups of
patients with the greatest reduction of pain from baseline
Table 1: Contributions of the variables to baseline SF-36 Mental Health scores
Correlation (r) with
Quantitative variables Mean STD Baseline SF36-MH R2 p-value
Baseline bodily pain 3.67 1.12 -0.36 0.130 <0.0001
Age 41.8 10.6 0.15 0.023 0.0121
Baseline SF36-MH
Categorical variables Category n Mean STD
Sex Male 166 61.25 19.88 0.002 0.5065
Female 110 62.95 19.35
Workers' compensation Yes 105 56.15 20.53 0.052 0.0001
No 171 65.47 18.27
Length of episode <=6 week 54 68.52 18.99 0.033 0.0109
6–26 weeks 133 61.29 17.95
>26 weeks 89 58.88 21.68 0.006 0.2024
Comorbid illnesses Yes 69 59.36 19.81
No 207 62.78 19.58
R2 from the model including all above variables 0.227
Note: R2 was calculated using the model including only one variable.
SF-36 MH scores range from 0–100, where 100 means "always happy and calm over past month."
280 (surgical+ non-surgical) patients have DNA, four patients, 3 missing baseline SF36-MH and 1 missing baseline bodily pain, were dropped from 
analysis
In covariate selection, linear regression with backward selection method (p = 0.1) was applied, where baseline Sf36-MH was dependent variables, 
age, sex, workers' compensation, baseline bodily pain, comorbid illnesses, patient group (nonsurgical vs. surgical), marital status, education, and 
prior episodes were independent variables, and age, sex and workers' compensation were fixed in the modelMolecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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Baseline mood vs. pain in 277 patients with subacute sciatica, regardless of subsequent surgical or nonsurgical treatment Figure 2
Baseline mood vs. pain in 277 patients with subacute sciatica, regardless of subsequent surgical or nonsurgical 
treatment. Overall intensity of "bodily pain" over the month before seeing a surgeon for sciatica explains about 13% of the 
variance in depressive and anxious feelings over the same period (p < 0.0001), assessed by the five-item SF-36 Mental Health 
Subscale (top panel). Higher scores on the y axis correspond to better mood. The other panels show similar relations to pain 
of the three items of the subscale pertaining to depressed mood (middle) and the two items pertaining to anxiety (bottom).Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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reported an immediate improvement in mood. Surpris-
ingly, the quartile of patients with the least improvement
in pain reported, on average, a small improvement in
mood from 6 to 24 months.
However, patients demonstrated considerable variability
in the relationship between pain and mood. Fig 4 shows
that there is a large amount of individual variability in
mood change from baseline to one year at each level of
acute surgical pain improvement. Table 2 shows the
results of a regression analysis of SF-36 MH scores at 12
months. More intense pain at the 3 and 6 month time
points (about 20% of variance), baseline depression and
anxiety (19% of variance), "crossing over" to surgery sev-
eral months after choosing nonsurgical treatment at base-
line (8% of variance), receiving workers' compensation at
baseline (4% of variance), and more intense pain at base-
line (1% of variance) were associated with more anxiety
and depression at 12 months.
Genetic analysis of relation between pain and mood
Chi-square tests showed that all SNPs used in the study
were in Hardy-Weinberg equilibrium. No polymorphism
in any of the three prespecified mood candidates, COMT,
BDNF, and 5HTT had a significant main effect on 12-
month mood, or a significant gene-pain interaction on
mood. None of the other 25 genes we examined showed
a strong enough association with the mood endpoint to
remain significant after correction for the multiple candi-
date genes, and where appropriate, for multiple analysis
models, or multiple SNPs within one gene. In order to
illustrate the method, however, we show the results for
the galanin-2 receptor. Three of the four SNPs tested in the
gene (Fig. 5) showed uncorrected p values of 0.003 to
0.008 for a recessive model of interaction with 3–6 month
pain to explain variance in 12-month mood. An analysis
of a haplotype incorporating these SNPs showed a nomi-
nally significant interaction term (p = .01). However, a
nominal p value < 0.001 would have been necessary to
Pain and mood over time after surgical discectomy Figure 3
Pain and mood over time after surgical discectomy. In each panel, the four curves represent subgroups of 153 surgical 
patients divided according to the percentage reduction in "bodily pain" from the baseline to the three month rating. Top left: 
Bodily pain plotted against time over three years postoperatively. Top right: SF-36 Mental Health scores plotted against time. 
Higher values on the y axis correspond to less depressed or anxious feelings. Note that mood sharply improves at the first 
postoperative point in the three subgroups of patients with 25–100% reduction in pain, but mood does not worsen in the 
group with minimal pain relief. Bottom: The items specifically related to depression (left) and anxiety (right) show similar rela-
tions to pain reduction.Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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Table 2: Contributions of the variables to 1-year SF-36 Mental Health scores
Correlation (r) with
Quantitative variables Mean STD 1 year SF36-MH R2 p-value
Mean bodily pain at 3 and 6 month 2.03 1.11 -0.450 0.203 <0.0001
Baseline SF36-MH 61.62 18.15 0.436 0.190 <0.0001
Baseline bodily pain 3.9 0.99 0.118 0.014 0.1642
Age 42.84 10.07 0.042 0.002 0.623
1 year SF36-MH
Categorical variables Category n Mean STD
Sex Male 86 74.88 20.34 0.001 0.724
Female 55 73.60 21.92
Workers' compensation Yes 42 68.00 25.05 0.040 0.018
No 99 77.09 18.44
Crossover 0 month 120 76.83 18.54 0.079 0.001
3 or 6 month 21 60.38 28.03
R2 from the model including all above variables 0.435
Note: R2 was calculated using the model including only one variable.
In covariate selection, linear regression with backward selection method (p = 0.1) was applied, where 1 year SF-36 MH was the dependent variable; 
age, sex, workers' compensation, baseline bodily pain, prior episodes, and the SF-36 General Health, Vitality, Social Function, and Emotional Role 
subscales were independent variables; and age, sex and workers' compensation were fixed in the model.
141 of 162 surgical patients with both 1 year mood data and all 7 covariates and DNA were used in the 1 year mood analysis.
"Crossover" refers to the time point when a questionnaire showed that a patient who initially chose nonsurgical treatment underwent lumbar 
discectomy.
Individual variation in improvement in mood over first year after discectomy plotted against the percent of bodily pain reduc- tion produced by surgery Figure 4
Individual variation in improvement in mood over first year after discectomy plotted against the percent of 
bodily pain reduction produced by surgery. Each point represents one patient.Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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correct for the 28 candidate genes and multiple analysis
models. With that caveat, we suggest that Fig. 6 illustrates
a pattern consistent with a neurochemical interaction
between pain and mood processing. In patients with 3–6
month pain levels of none to moderate (0–3), GAL2R
genotype did not appear to affect 12-month mood. In
patients with residual pain that was moderate/severe,
severe, or very severe (3.5–5), patients with one or two
copies of the common allele of this SNP had greater emo-
tional distress (i.e., lower SF-36 Mental Health scores)
than patients homozygous for the uncommon allele.
Baseline mood scores
Results of genetic analyses for baseline mood were similar
to those for the 12-month mood data. No polymorphism
in COMT, BDNF, and 5HTT had a significant main effect
on baseline mood, or a significant gene-pain interaction
on mood. None of the other 25 genes showed a strong
enough association with the mood endpoint to remain
significant after correction for multiple testing. However,
three SNPs in the mu opioid receptor gene (Fig. 7) showed
nominally significant pain-gene interactions on baseline
mood, with p values ranging from 0.006 to 0.02. Fig. 8
shows that at baseline levels of pain from 0 – 3 (none-
moderate), the relation between genotype and mood is
similar. However, patients who are homozygous for the
uncommon allele at rs495491 appear more susceptible to
late emotional distress at high pain levels than patients
with at least one copy of the common allele.
Discussion
These data illustrate an approach to investigating causal
relationships among pain, mood, and genetic polymor-
phisms patients who undergo a surgical procedure that
produces variable degrees of pain relief. The degree of sur-
gical relief of pain at the first two postoperative time
points explains 20% of the variance in mood at 1 year (p
<0.0001), but there is also additional inter-individual var-
Galanin-2 receptor gene Figure 5
Galanin-2 receptor gene. Physical locations of the four genotyped single nucleotide polymorphisms (SNPs). Coding exons 
are shown as solid blocks. SNP locations are from the SNP Browser software and the Panther Classification System public 
database, February, 2006. P values for the effect on one-year SF-36 Mental Health scores of the SNP x 3–6 month pain interac-
tion term are shown above each SNP.Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
Page 10 of 15
(page number not for citation purposes)
iation in mood (Fig. 4), some of which may result from
inherited genetic variation. Because surgical relief of pain
is a large abrupt change occurring at a fixed time point,
this experimental design is well-suited for studying physi-
ological events over time.
Although the galanin-2 receptor and mu opioid receptor
are plausible candidates to mediate effects of pain on
mood, and showed graphical patterns consistent with a
pain-gene interaction, we cannot prove these specific
effects because of our modest sample size. Although this
was the largest prospective study of pain from a uniform
lesion that we could identify at the outset of the project, a
several hundred patient cohort does not provide sufficient
power to correct for the tests of dozens of genes and mul-
tiple analytical models unless the relative risk conferred
by the polymorphism is more than 2.5, larger than most
common polymorphisms for which a link to medical dis-
eases have been established [29]. However, major medical
centers perform thousands of many types of pain-reliev-
ing operations each year, making possible more powerful
searches of this type. The number of simultaneous statis-
tical tests supported by candidate studies increases steeply
with sample size. For example, just an eight-fold increase
in N permits a million-fold increase in independent tests,
sufficient to examine the genome in detail [29].
Another limitation of this study is the lack of clinical diag-
nosis of anxiety or depressive disorder. Across cohorts of
patients, the SF-36 MH subscale correlates strongly with
research psychiatric diagnoses and changes with success-
ful treatment, but cannot provide individual diagnoses
[20]. The SF-36 pain measure does not have optimal pre-
cision either, for estimating the actual pain level over
many months. Bellamy et al. [31] found that a 0–10 point
numerical scale and 100 mm VAS were more sensitive
than a 5-category pain intensity scale, while Jensen and
McFarland [32] reported that the average of 7 pain meas-
urements at different times gives a better estimate of
actual pain than 1–2 measurements. Quality of life
researchers are currently seeking to improve diagnostic
precision with computerized adaptive algorithms that
choose items to hone in on each subject's response range.
It is possible that some of patients with the most severe
mood disorder may have refused to return questionnaires
Pattern of interaction between galanin-2 receptor SNP and residual pain upon 12-month mood score Figure 6
Pattern of interaction between galanin-2 receptor SNP and residual pain upon 12-month mood score. SNP rs8836 showed 
a significant interaction term in the recessive model (p = 0.003, uncorrected for multiple tests). The 12 month SF-36 MH mood scores 
are plotted against the mean of bodily pain scores at 3 and 6 mos. Each point is the mean 12-month mood for all of the patients with that 
bodily pain score and genotype. The curve connecting the triangles represents 33 patients homozygous for the uncommon allele; the 
curve connecting the filled circles represents 93 patients with one or no copies of the uncommon allele. In the presence of high residual 
postoperative pain, 2 copies of the uncommon allele appear to be associated with relative protection against symptoms of depression and 
anxiety, but the small numbers of such patients make this result illustrative, not statistically persuasive.Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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or contribute DNA, lessening the study's power to exam-
ine this link. Another possible gap is that in the 16 years
since this study was begun, pain psychologists learned
that styles of coping with pain and environmental stres-
sors are as important determinants of many pain out-
comes as mood. This study did not include detailed
measurements of pain catastrophizing [33], pain self-effi-
cacy, and stressors in the work and personal environment
[34], which one might consider for a new prospective
study of pain and mood.
While we cannot exclude a false positive in this study, the
possible mood mediating effects of the galanin-2 and mu
opioid receptor polymorphisms should be studied in
additional cohorts of patients with pain. The neuropep-
tide galanin is widely expressed in the central nervous sys-
tem, including areas regulating emotionality [35]. It has
been implicated in a wide range of physiological func-
tions including pain control and cognition and in behav-
iors such as anxiety and depression [36]. We recently
reported that haplotypes in the galanin gene were associ-
ated with anxiety-associated alcoholic phenotypes in
humans [37]. The three galanin receptor subtypes,
GALR1, GALR2, and GALR3 [38], are widely distributed in
mood-related brain areas such as hypothalamus, central
amygdaloid nucleus, and thalamus [39] and may mediate
anxiety-associated behavior [40]. No common functional
polymorphism has yet been identified in the human
GALR2 gene. There is strong linkage disequilibrium (LD)
between all SNP pairs we genotyped, and on the related
chromosome region (HapMap; http://www.hapmap.org).
Although the SNPs used in our study are not located
within GALR2, they are within 5 kb of the start and end
sites of the gene (Fig 4), and are within a haplotype block
encompassing GALR2, its regulatory elements, and neigh-
boring genes. The nominally significant pain-gene inter-
action on mood of three out of four SNPs in this region
and the haplotype may reflect the contribution of a func-
tional allele in GALR2  or the genes located nearby.
The mu opioid receptor is also a plausible candidate to
mediate between pain and mood. The endogenous opioid
system and µ-opioid receptors modulate affective behav-
iors [41] as well as affective components of acute pain
Mu opioid receptor gene Figure 7
Mu opioid receptor gene. Physical locations of the eight genotyped single nucleotide polymorphisms (SNPs). Coding exons are shown 
as solid blocks. SNP locations are from SNP Browser software and the Panther Classification System public database, February, 2006. P 
values for the effect on one-year SF-36 Mental Health scores of the SNP x 3–6 month pain interaction term are shown above each SNP. 
SNP #1 m tge wekk-known Asn 40 Asp polymorphism, was not associated with mood scores.Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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[22]. Opioid treatment of chronic pain is often accompa-
nied by striking improvements in mood [42]. Although
the human mu opioid receptor gene (OPRM1) has poly-
morphisms that affect receptor function and are associ-
ated with some behavioral phenotypes [43], no
associations with depression and anxiety disorders have
yet been reported [44]. The three OPRM1  SNPs most
closely associated with pain-related mood scores in our
study are in high linkage disequilibrium and in the same
haploblock, which also includes the previously reported
functional non-synonymous SNP Asn40Asp (rs1799971).
However, the latter SNP was not associated with mood
scores. Therefore we assume that the association signal, if
replicated, could be attributable to another functional
allele that is still unknown.
In this study, we have tested mood effects of genes that we
had already genotyped based on their involvement in
chronic pain processing. For future studies on pain-mood
interaction, one might select additional candidate genes
reportedly associated with anxiety and depression; e.g.,
the genes for corticotropin-releasing hormone (CRH)
[45], the adenosine A(2A) receptor [46], the dopamine
D4 receptor [47], and tryptophan hydroxylase [48].
It is interesting that among patients in the quartile with
the least surgical pain relief, mood did not deteriorate,
and actually improved from 6 months on. Within this
quartile of patients (Fig. 4), for example, pain levels at 24
months after surgery were equivalent to the presurgery
levels, but mood at 24 months was considerably
improved from baseline. It would be interesting to exam-
ine individual differences in resilience factors, including
genetic resilience factors, that are associated with
improvements in mood in the face of the surgical failure
to relieve pain.
The preceding analysis of gene effects mediating mood
responses to unrelieved pain in surgical patients is a gene
× environment (G × E) interaction study. Thus far, the
most widely cited examples of G × E interactions on
behavioral endpoints [17,18] involve an environmental
Pattern of interaction between mu opioid receptor SNP and baseline pain upon baseline mood score Figure 8
Pattern of interaction between mu opioid receptor SNP and baseline pain upon baseline mood score. SNP rs495491 was 
one of the three SNPs that showed a significant interaction term in the recessive model (p = 0.003, uncorrected for multiple tests). The 
baseline SF-36 MH mood scores are plotted against the baseline bodily pain scores. Each point is the mean baseline mood for all of the 
patients with that bodily pain score and genotype. The curve connecting the triangles represents 17 patients homozygous for the uncom-
mon allele; the curve connecting the diamonds represents the 252 patients with one or no copies of the uncommon allele. In the pres-
ence of high baseline pain, 2 copies of the uncommon allele appear to be associated with symptoms of depression and anxiety, but the 
modest sample size and multiple genes tested make this result illustrative, not statistically persuasive. Data from patients with baseline 
pain of 0–2 (none, very mild, or mild) were pooled because few patients had such low pain scores at presentation.Molecular Pain 2006, 2:14 http://www.molecularpain.com/content/2/1/14
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stress. Although our most suggestive results for the genes
we examined pertained to unique pain-gene interactions
on mood, the same analytic method might help to iden-
tify other genes that have a general effect on mood, dem-
onstrated by a main effect in the regression. A potential
advantage of this study design is that patients are all sub-
ject to a similar stress – several months of a painful condi-
tion followed by major surgery – and then experience
variable levels of residual pain, a stressor that can be well-
quantified and corrected for in the analysis. Without
detailed measurements of environmental stress, it may be
difficult to identify genes for depression or anxiety. For
example, although twin studies suggest that the heritabil-
ity of unipolar major depression disorder is 40–50% [49]
it has been difficult to replicate candidate gene associa-
tions, possibly because the environmental circumstances
triggering depression are so varied [50]. A major surgical
procedure may provide a somewhat uniform stressful sit-
uation. Within this setting, the two factor analysis shown
above may remove a large amount of variance in late
mood due to pain, increasing sensitivity to a main effect
of a genetic polymorphism involved in general mood-reg-
ulating mechanisms not specific to patients with pain.
It is possible that alternative statistical methods may bet-
ter detect "mood" or "pain-mood" genes in the types of
surgical cohort studies illustrated above. For example,
patients without any pain might be excluded from the
pain-mood analyses, or different time-points might be
chosen for the pain and mood variables. The relative mer-
its of alternative methods can be compared more persua-
sively once a robust gene effect is identified to use as a
gold standard.
Conclusion
A better understanding of the specific mechanisms linking
pain and mood may open up a set of new interventions to
decrease the morbidity of chronic pain conditions. Basic
science studies in animals [13,50] including microarray
search methods are likely to yield a long list of candidates.
We have demonstrated a simple method to search for
genetic polymorphisms that contribute to interindividual
variation in the manner in which pain produces depres-
sion or anxiety, using cohorts of patients who have under-
gone a surgical procedure that variably relieves pain.
Cross-correlation with the results of the types of human
genetic approaches outlined here may help researchers to
prioritize targets and develop treatments or prophylactic
interventions for pain-specific depression and anxiety.
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